Table 3.
HI | ON | MA | AU | SE | |
---|---|---|---|---|---|
Which genetic results were offered, and to whom? | |||||
MMR mutations | |||||
To cases | Y | Y | Y | Y | Y |
To their relatives | Y | Y | Y | Y | Y |
Biallelic MutYH mutations | |||||
To cases | Y | Y | Starting | Y | Y |
To their relatives | Y | Y | Starting | Y | Y |
VUS | |||||
To cases | Y | Y | N | N | Y |
To their relatives | N | N | N | N | N |
Familial Colorectal Cancer Type X | |||||
To cases | Y | Y | N | N | Y |
To their relatives | N | Y | N | N | N |
Protocols for returning genetic results | |||||
Who provides counseling? (genetic counselor [GC]) | Study GC | GC shared by study and hospital | Study MD or GC | Government-funded GC service | Study GC |
Mode of delivery of genetic counseling | In-person/telephone | In-person/telephone | Telephone | In-person | In-person/telephone |
Participant encouraged to seek CLIA-approved testing | Yes | NAa | Yes | NAa | Yes |
CLIA Clinical Laboratory Improvement Amendments
aTesting offered through clinical services